Related Experiment Videos
[Multiple sclerosis: update on current therapies]
1Department of Neurology, Kohnodai Hospital.
Abstract:
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS). It is widely accepted that MS is caused by an autoimmune response against myelin. The most common treatment for acute attacks or active state of exacerbation of MS is intravenous pulsed methylpredonine therapy followed by immunosuppressive agents, such as corticosteroid or azathioprine. Recently, recombinant interferon beta-1b, or natural form of interferon beta-1a has been reported to have an effect in MS. We reported preliminary results on a new method of lymphocytapheresis using a leucocyte adsorption column to treat MS patients in active state. In some MS patients, immediate improvement was observed following lymphocytapheresis. The more selective therapeutic trials including monoclonal antibodies against chimeric CD4, anti-antigen receptors antibody, anti-adhesion molecules antibody, and the induction of tolerance to myelin basic protein, or immunity to TCR antagonist peptides were reported in several institutes based on new strategies in immunotherapy.
Insights
This study explores lymphocytapheresis as a novel treatment for active multiple sclerosis (MS), an autoimmune CNS disease. Preliminary results show immediate improvement in some MS patients, suggesting a new immunotherapy approach.
Area of Science:
- Neuroimmunology
- Central Nervous System (CNS) Disorders
- Autoimmune Diseases
Background:
- Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the CNS.
- MS is understood to result from an autoimmune response targeting myelin.
- Current treatments include corticosteroids, azathioprine, and interferons, with ongoing research into novel immunotherapies.
Purpose of the Study:
- To report preliminary findings on lymphocytapheresis using a leukocyte adsorption column for treating active MS.
- To evaluate the efficacy of this new method in MS patients experiencing exacerbations.
Main Methods:
- Lymphocytapheresis utilizing a leukocyte adsorption column was employed.
- The treatment was administered to patients with multiple sclerosis in an active state.
Main Results:
- Preliminary results indicate immediate improvement in some MS patients following lymphocytapheresis.
- This suggests a potential therapeutic benefit of the procedure in managing active MS.
Conclusions:
- Lymphocytapheresis represents a promising new method for treating active multiple sclerosis.
- Further selective therapeutic trials, including monoclonal antibodies and tolerance induction, are being investigated for MS immunotherapy.